Title for MeetingAbstracts
Alphabetical listing of titles
Ampicillin [AMPI] and Ester Prodrugs of AMPI are not Substrates of MRP and P-gp in J774 Macrophages [M&Phi_upper;].
Ampicillin Resistance of Haemophilus influenzae in Portugal: Phenotypic Characterization and Molecular Epidemiology of Non-beta-Lactamase-Producing Strains.
Ampicillin-Sulbactam Treatment for Nosocomial Multiresistant Acinetobacter baumanii Bacteremia.
Amplification of HIV 1 provirus from CSF and its correlation with neurological disease.
Amplification of HIV gag and env genes from kidney biopsy archival material.
Amplification of HIV-1 gag gene from microdissected cells of kidney biopsy archival material.
Amplification of HIV-1 provirus in CSF and neurological disease in HIV-infected children.
Amplification of the BCG 85-B gene from the Mycobacterium avium complex using thermophilic strand displacement amplification.
Amplification of viral replication relevantly with reverse differentiation in HIV-1 infected cells with macrophage phenotype.
Amplified ELISA anti-CMV IgM antibodies for early diagnosis of cytomegalovirus disease in AIDS patients.
Amplified enzyme immunoassay for detection of HIV-1 infection in donated blood after screening test nonreactive.
Amplified Fragment Length Polymorphism (AFLP) in the Epidemiology of Candida Species Colonization in Pediatric Stem Cell Transplantation (SCT).
Amplifying voices, catalysing debate, facilitating change- working with the media on HIV/AIDS in South Asia.
Amprenavir (141W94, APV USAN approved)/3TC/ZDV is superior to 3TC/ZDV in HIV-1 infected antiretroviral therapy-naive subjects.
Amprenavir (141w94, APV USAN approved): review of overall safety profile.
Amprenavir (141W94, APV)/3TC/ZDV Exerts Durable Antiviral Activity in HIV-1-Infected Antiretroviral Therapy-Naive Subjects through 48 Weeks of Therapy.
Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg QD given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART-naive HIV-1- infected adults over 12 weeks (APV20001).
Amprenavir (APV) and ritonavir (RTV): intraindividual comparison of different doses and influence of concomitant NNRTI on steady-state pharmakokinetics in HIV-infected patients.
Amprenavir (APV) Plasma and Intracellular Concentrations when Coadministered with Ritonavir (RTV) in Twice and Once Daily Regimen in HIV-Infected Patients.
Amprenavir (APV) plasma concentrations are dramatically increased by association with ritonavir (RTV) baby-doses in HIV-infected patients (pts): possible combination with efavirenz (EFV).
Amprenavir (APV) Shows Less Protease Inhibitor (PI) Cross Resistance as Compared with Other PIs in a Multiexperienced HIV Cohort (CNAB3008, French Virological Substudy).
Amprenavir has antipneumocystis effect in vitro.
Amprenavir in salvage therapy: good virological and immunological response in a cohort of 45 patients.
Amprenavir is an Effective Inducer of Delavirdine Metabolism: A Steady-State Pharmacokinetic Interaction Study between Amprenavir and Delavirdine in Healthy Volunteers.
Amprenavir Resistance Associated with Emergence of HIV Protease Mutation I54M.
Amprenavir trough concentrations in HIV patients receiving chronic salvage therapy with amprenavir and lopinavir.
Amprenavir(141W94) in combination with 1592U89 is highly synergistic in vitro.
Amprenavir, Efavirenz and Ritonavir as a salvage regimen for heavily pre-treated individuals.
Amsterdam Cohort Study: presence of the variant mannose-binding lectin (MBL) alleles associated with slower progression to AIDS?
Amsterdam Cohort Study: presence of the variant mannose-binding lectin (MBL) alleles associated with slower progression to AIDS?